There is a moment in every pharmaceutical company’s strategic planning cycle when the pipeline review tells an uncomfortable story. The internal R&D engine, however well-funded and well-staffed, cannot fill every gap. Therapeutic areas go undercovered. Late-stage assets are needed faster than internal programmes can deliver them. Molecules with genuine commercial potential sit in the portfolio without the development infrastructure to advance them efficiently. This is the moment when licensing — both in and out — stops being a theoretical option and becomes an operational necessity.
Pharmaceutical licensing deals are among the most consequential strategic transactions a company will execute. They are also among the most misunderstood. The mechanics are complex, the valuation frameworks are non-trivial, and the negotiation dynamics require a precise understanding of what each party actually needs from the arrangement. This primer covers the fundamentals — and the data — that every pharma executive should have at their fingertips before entering a licensing discussion.
🔑 Licensing-In: Acquiring External Innovation
Licensing-in is the process of acquiring rights to a compound, technology platform, or intellectual property developed externally — typically from a biotech company, academic institution, or another pharmaceutical company seeking a development or commercialisation partner.
The strategic rationale is straightforward: internal R&D alone cannot generate the volume and diversity of pipeline assets required to sustain a pharmaceutical company’s long-term commercial position. Licensing-in provides access to innovation that has already cleared at least some of the early-stage scientific risk, at a cost structure that is typically more capital-efficient than building equivalent programmes internally.
What the Data Shows
The scale of licensing-in activity in the global pharmaceutical industry has grown substantially. In 2024, the total value of announced pharmaceutical licensing agreements — including upfront payments, milestones, and royalties — exceeded USD 185 billion globally, according to industry transaction databases. The average upfront payment in a Phase II licensing-in deal reached USD 148 million in 2024, up from USD 89 million in 2020 — a 66% increase in four years that reflects both the increasing quality of externally developed assets and the intensifying competition among large pharmaceutical companies to access them.
The therapeutic areas attracting the highest licensing-in valuations in 2024 and 2025 are oncology, which accounts for approximately 38% of all licensing deal value, followed by immunology and inflammation at 19%, and rare diseases at 14%. Neuroscience, historically underrepresented in licensing activity due to its development complexity, has grown its share substantially — driven by the emergence of validated mechanisms in Alzheimer’s disease, Parkinson’s disease, and psychiatric conditions.
Key Licensing-In Structures
Licensing-in deals are structured in several ways depending on the stage of the asset, the geographic scope of the rights being acquired, and the respective capabilities of the parties:
- Exclusive worldwide licence — the licensee acquires sole rights to develop and commercialise the asset globally. Commands the highest upfront payment and milestone obligations.
- Exclusive territorial licence — rights are limited to defined geographies. Common where the licensor retains commercial capability in certain markets and seeks a partner for others.
- Co-development and co-commercialisation agreement — both parties share development costs and commercial economics. Appropriate where both parties have complementary capabilities and neither wishes to fully divest rights.
- Option agreement — the licensee pays for the right to licence the asset after defined data readouts, limiting upfront capital commitment while securing access to the asset before competition intensifies.
The option-to-licence structure has grown significantly in popularity. In 2024, option agreements represented 27% of all early-stage pharmaceutical licensing transactions — up from 14% in 2019 — reflecting a broader industry preference for staged capital commitment in an environment of elevated development risk and capital cost.
📤 Licensing-Out: Monetising Internal Assets
Licensing-out is the mirror transaction — a pharmaceutical company grants rights to an internally developed asset to an external partner in exchange for financial consideration and, typically, development or commercialisation capability the licensor does not possess or does not wish to deploy in a given geography or indication.
The strategic rationale for licensing-out is equally compelling, and it operates across several distinct scenarios.
Pipeline prioritisation is the most common driver. No pharmaceutical company has the development infrastructure or capital to advance every asset in its portfolio simultaneously. Licensing-out non-priority assets generates revenue — upfront payments, development milestones, and royalties — that can be redeployed into higher-priority programmes, while ensuring that deprioritised assets continue to be developed rather than shelved.
Geographic reach is the second major driver. A pharmaceutical company with strong development and commercial capability in Europe and Asia-Pacific may lack the infrastructure to commercialise an asset effectively in Latin America, the Middle East, or Sub-Saharan Africa. Licensing-out to regional partners with established market access infrastructure is frequently the most capital-efficient route to global revenue.
Indication expansion is a less obvious but increasingly important driver. An asset developed for one indication may have mechanistic potential in adjacent therapeutic areas that the originating company lacks the expertise or appetite to pursue. Licensing-out for specific indications allows the originator to capture value from that potential without diverting internal resources.
The Economics of Licensing-Out
The financial structure of a licensing-out deal typically comprises four components:
- Upfront payment — a non-refundable cash payment at signing, reflecting the value of the rights being transferred and the competitive dynamics of the negotiation. In 2024, the median upfront payment in a Phase I/II out-licensing deal was USD 52 million.
- Development milestones — contingent payments triggered by defined clinical and regulatory events: Phase II initiation, Phase III completion, regulatory submission, and approval. Total milestone packages in major licensing deals frequently exceed USD 500 million to USD 1 billion, though the probability-weighted value of those milestones is substantially lower.
- Sales milestones — contingent payments triggered by achieving defined annual net sales thresholds in the licensed territory.
- Royalties — a percentage of net sales payable to the licensor for the duration of the agreement, typically ranging from 8% to 15% for a mid-stage asset and 15% to 25% for a late-stage or approved asset with demonstrated commercial potential.
⚖️ Valuation: The Framework Every Executive Needs
The most technically demanding aspect of any licensing negotiation is asset valuation. The industry standard approach is risk-adjusted net present value (rNPV) — a discounted cash flow model that applies probability of success estimates at each clinical development stage to the projected commercial cash flows of the asset.
The key inputs are:
- Peak sales forecast — typically derived from epidemiological data, pricing benchmarks, and competitive landscape analysis
- Probability of success by stage — industry benchmarks suggest Phase I to approval success rates of approximately 10% to 12% overall, with substantial variation by therapeutic area
- Development timeline and cost — including the cost of capital, which at current rates materially affects the present value of distant cash flows
- Royalty rate and milestone structure — which determine how the total value is split between licensor and licensee
A common rule of thumb in licensing negotiations is that the licensor should capture approximately 20% to 30% of the rNPV of the asset in the combined value of upfront payment, milestones, and royalties — though this varies significantly with asset stage, therapeutic area, and competitive interest.
🌏 The Asia-Pacific Licensing Landscape
The Asia-Pacific region has become one of the most active and strategically significant licensing markets in the global pharmaceutical industry. Regional pharmaceutical companies — particularly those based in Japan, South Korea, China, and increasingly South-East Asia — are both significant licensors of internally developed assets to global partners and significant licensees of global assets seeking regional development and commercialisation partners.
In 2024, Asia-Pacific pharmaceutical companies were parties to licensing agreements with a combined announced value of more than USD 34 billion — representing 18% of global licensing deal value, up from 11% in 2020. The growth reflects both the increasing scientific quality of Asia-Pacific pharmaceutical R&D and the growing commercial attractiveness of Asia-Pacific markets to global pharmaceutical companies seeking regional partners with established regulatory and market access expertise.
For pharmaceutical executives operating in or targeting Asia-Pacific markets, understanding the regional licensing landscape — including the regulatory frameworks governing technology transfer, the IP protection environment in individual markets, and the commercial dynamics of regional distribution partnerships — is increasingly a core strategic competency.
💡 Key Takeaways for Pharma Executives
Licensing-in and licensing-out are not peripheral activities for pharmaceutical companies that cannot develop everything internally. They are central strategic tools that the most commercially successful pharmaceutical companies deploy deliberately, systematically, and with sophisticated financial and operational frameworks.
The data is clear: deal volumes are growing, valuations are rising, and the competition for high-quality assets is intensifying. Executives who understand the mechanics of deal structure, the discipline of rNPV-based valuation, and the strategic logic of when to licence in versus when to licence out are better positioned to create durable competitive advantage — and to avoid the value-destructive mistakes that come from entering licensing negotiations without that foundation.
The pipeline gap is real. The licensing market is active. The question is whether your organisation is approaching it with the rigour and strategic clarity it deserves.
